Skip to main content

Conference Program

Subpage Hero


2024 ACMG Foundation Awards and Presidential Plenary Session: Inquiry and Innovation – How Far Have We Come and How Far Can We Go?

13 Mar 2024
Venue: Metro Toronto Convention Center
Meeting Room: Exhibit Hall FG
Health Services & Implementation
  • Accredited:
    • Accredited
  • Primary Categories:
    • Health services and Implementation
  • Secondary Categories:
    • Health services and Implementation
Gregor Mendel, known as the “father of genetics,” was born just over 200 years ago. Barbara McClintock, the founder of cytogenetics, graduated college just over 100 years. Our growth and knowledge of DNA and its function and importance has advanced exponentially over the years. Initially DNA was described as life’s instruction manual. Later, DNA was compared to an advanced computer program. We all know DNA is so much more.

The American College of Medical Genetic and Genomics was founded over 30 years ago. Since then, genetics has been integrated into all aspects of healthcare and medicine. Personalized or precision medicine has emerged as an innovative approach incorporating a patient’s genes and environment. Individualized care is critical as a one size fits all approach does not always work for all patients.
In the last few years, artificial intelligence (AI) has emerged as a new tool and can help healthcare professionals in possible diagnoses or even in the administration of the practice of medicine. However, proceeding with caution is prudent especially in clinical and laboratory genetics, as not all of our practices fit into specific algorithms.

This plenary session will explore several issues related to inquiry and innovation related to DNA, genetics, and healthcare.  We will start with a historical perspective.  We will explore the juxtaposition of prenatal genetic screening and cancer diagnoses. We will also investigate artificial intelligence and its potential role in our practice. Lastly, we will explore ACMG’s role in clinical genetics research and how our current and possible future portfolios can contribute to community efforts in medical genetics and genomics. Our research can guide us toward future discoveries in genetics and genomics.

Learning Objectives

  1. Discuss the evolution of our understanding of genetics and inherited diseases
  2. Recognize maternal malignancy as a rare cause of abnormal and/or unusual prenatal cfDNA screening
  3. Examine the emergence of artificial intelligence in healthcare
  4. Summarize ACMGs role in genetics and genomics research specifically newborn screening data collection and support for ClinGen